Nanobac, Eureka Genomics Ink Definitive Merger Deal

The merger will combine Eureka's bioinformatics capabilities with Nanobac's drug discovery program focused on inhibiting, destroying, or neutralizing calcifying nanoparticles.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories